OSTAR Launches G4™ First Cell Enabled Multifunction TeleHealth Gateway for Diabetes / CHF

VANCOUVER, Wash., March 9, 2015 /PRNewswire/ -- OSTAR Healthcare Technology, a Washington State-based Telehealth Solutions company, announced the global launch of its G4 Device Gateway. This revolutionary HIPAA compliant Vendor Neutral Gateway (VNG) provides seamless remote device integration and monitoring for devices such as multi-vendor Glucometers, Vital Signs, Blood Pressure and Weight Scales. According to Doug Hemenway, President and CEO, "This global launch of the G4 brings forth the first patient-centered Vendor Neutral Gateway (VNG) to the market, integrating multiple vendors devices in the growing need for remote monitoring in telehealth. The G4 assists patient engagement and compliance in lockstep with 30-Day readmission rate reduction edicts. All OSTAR products reinforce OSTAR's commitment to improving patient outcomes, while avoiding unnecessary costs, complying with the Accountable Care Act (PPACA)."

Photo - http://photos.prnewswire.com/prnh/20150306/180075

Photo - http://photos.prnewswire.com/prnh/20150306/180076

OSTAR Healthcare Technology – G4 Multifunction Gateway provides payers, providers and patients with choice / control of Glucose meters and associated Glucose strips plus various vital signs monitoring. Furthermore, the device automatically connects to cell phone networks, seamlessly sending relevant data to Case Management, Population Health Management, EMRs and HIEs anywhere in the world. OSTAR's G4 Remote Telehealth Vital Signs Monitoring System is the first release of the device gateway series for vital signs monitoring systems. "Given the current transformation of healthcare and trend to remote telehealth in the United States, this vendor-neutral concept changes the game, providing choice for all stakeholders, such as insurance companies, brokers, TPAs and self-funded employer groups, reducing the cost of chronic disease management. The concept has the potential to impact shared saving plans in Accountable Care Organizations, while also positively impacting health insurance indicators such as HEDIS, with regards to Medicare Advantage Star Rating programs," stated by Dr. Paul A. Markham, President of V3 Healthcare Strategies. The result is reduced cost to healthcare systems and ultimately, to the American healthcare consumer.

About OSTAR Healthcare Technology

Based in Vancouver, Washington, OSTAR's Suite of unique Next Generation Patient Monitoring solutions brings forth superiority over conventional products' specification, quality and lower price; we challenge entire global hospitals blood pressure and oximeter measuring instruments.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.